Introduction
Allogeneic BM or haematopoietic SCT (ABMT/AHSCT) is a highly effective therapy in haematological malignancy, resulting in increased definitive cure rates or extended disease-free survival in various high-risk haematological diseases. 1 However, the procedure is associated with significant morbidity and mortality, which is especially high when referral to the intensive care unit (ICU) is required because of major organ dysfunction. ICU admission is necessary in 24-40% of ABMT/AHSCT patients during the phase of conditioning, engraftment and recovery, 2, 3 and in 19% of patients after the initial transplant. 4 Providing prolonged ICU treatment in these patients in case of multiple organ failure has been considered as inappropriate care, as their survival is judged to be disproportionately low with regard to the invested resources and the endured suffering of the patients and their beloved during ICU stay. [5] [6] [7] In earlier studies, investigators aimed to identify subsets of ABMT/AHSCT patients in whom ICU care is considered futile, stratifying patients into categories with increasing degree of organ failure or requirement of organ support, such as acute respiratory failure necessitating mechanical ventilation (MV), shock requiring vasopressors or acute kidney injury with the need for renal replacement therapy (RRT). [8] [9] [10] However, apart from a measure of organ failure itself, its underlying cause may be an important factor predicting outcome. For instance, it has been found that acute respiratory failure in cancer patients caused by reversible and/or treatable conditions has a better prognosis than acute respiratory failure resulting from irreversible or intractable disease, or when its cause remains unclear. [11] [12] [13] In this study, we report on the shortand longer-term outcome of a cohort of ABMT/AHSCT patients admitted to our ICU between 2000 and 2007, relating prognosis to the cause of critical illness.
Patients and methods
This study was conducted at the medical ICU of the Ghent University Hospital, a tertiary care academic centre with 1062 beds, and included all consecutive ABMT/AHSCT patients admitted from January 2000 to December 2007. The 14-bed medical ICU is staffed by three full-time intensive care physicians working according to the closedunit principle. A senior staff physician is present and consultants of different disciplines are available 24 h a day, 7 days a week. Important changes in management and all end-of-life decisions are taken in collaboration with the attending haematologist after having communicated treatment options and prognosis with the patients and/or their relatives. 12, 14 Patients admitted to this unit are at least 15 years old. In general, only patients with haematological malignancy, with a potentially favourable long-term prognosis, are referred to this unit in case of life-threatening medical conditions. Those patients who are less severely ill and who are unlikely to require ventilator support are usually referred to the BMT unit, or to the coronary care unit in the event of cardiac complications.
For all patients who received myeloablative conditioning, the prophylaxis regimen for GVHD consisted of MTX IV (given on days þ 1, þ 3, þ 6 and þ 11; the last dose was omitted or at least reduced in most patients because of severe mucositis, and CYA was given i.v. until oral administration was possible. For reduced intensity conditioning transplants, CYA was given in combination with mycophenylate mofetil. The duration of immunosuppressive treatment depended both on the donor (matched related donors vs matched unrelated donors) and on the presence of GVHD.
We prospectively collected all required data with particular attention to organ failure on ICU admission and during ICU stay, as well as data on the principal admission diagnosis. Severity of organ failure was assessed by means of the sequential organ failure assessment score starting from ICU admission until day 5 in the ICU. [15] [16] [17] [18] The principal admission diagnosis was assessed by an independent panel of three physicians blinded to patients' outcome, and by at least two senior staff members experienced in the management of critically ill cancer patients within 48 h of ICU admission from 2005 onward. 12 Here, patients were categorized according to the presence or absence of infection triggering critical illness. Patients with infection were further categorized according to the microbial aetiology (bacterial and non-bacterial) of infection. Differences between observers were resolved by consensus. In addition to the total constellation of signs, symptoms and ancillary data retrieved from the data pertaining to the patients, the panel used existing working definitions as previously defined to improve classification of patients. 12 Patients were considered to have pulmonary bacterial infection if they met the following criteria: (1) body temperature o36.0 1C or 438.0 1C, or hypotension; (2) dyspnoea or cough; 3) new pulmonary infiltrate on chest X-ray for which a non-bacterial or non-infectious complication was unlikely on the basis of the clinical circumstances and immune status, 12 or had been excluded otherwise. Pulmonary bacterial infection was considered documented in case a bacterial strain was isolated from blood, pleural fluid or from an adequate lower respiratory tract sample, and as clinically suspected in case no causal strain was isolated. Patients were diagnosed with documented non-pulmonary bacterial infection in case of altered body temperature and/or hypotension, together with bacteraemia or a positive bacterial culture obtained from an otherwise sterile site. Blood cultures were considered as positive when at least one culture showed growth of a bacterial strain or when at least two cultures sampled at different times showed growth of coagulase-negative Staphylococci or Corynebacterium spp. Patients were diagnosed with clinically suspected non-pulmonary bacterial infection if both, altered body temperature and hypotension, were present, or if one of these was present, together with obvious clinical, radiological or biochemical evidence of systemic inflammation compatible with bacterial infection at the site of infection. Patients were diagnosed with fungal infection if they met the criteria of documented or probable fungal infection as defined by the 2002 international consensus meeting. 19 Pneumocystis jirovecii pneumonia was diagnosed by positive direct fluorescent Ab or by specific BAL or pulmonary biopsy examination (Grocott-Gomori stain). CMV disease was diagnosed as positive quantitative PCR for CMV, together with a compatible clinical picture.
For diagnosis of GVHD, international staging criteria were used (Ball et al. 20 for acute GVHD, 21 for chronic GVHD). If possible, a biopsy was taken to confirm the diagnosis, and then the biopsy grade determined the grade of the GVHD. If more than one organ was affected, the highest grade of each organ determined the overall grade.
Continuous variables are described as mean (±s.d.) or median (interquartile range), and categorical variables are described as counts (percentage). For comparative tests on continuous variables between categories of patients, the non-parametric Kruskal-Wallis test was used. For categorical variables, the Pearson w 2 -test was used. All reported P-values are two-tailed, and are considered statistically significant when Po0.005. Logistic regression analysis was used to adjust the relationship between outcome (in-hospital mortality) and patient characteristics. All statistical analyses were run with SPSS 10 (Chicago, IL, USA).
Results
A total of 44 ABMT/AHSCT patients were admitted to our ICU during the study period. The underlying haematological disease was acute myelogenous leukaemia in 19 (43%) patients, acute lymphoblastic leukaemia (including highgrade non-Hodgkin's lymphoma) in 13 (30%), multiple myeloma in 6 (14%), chronic myelogenous leukaemia in 3 patients, low-grade non-Hodgkin's lymphoma in 1, Hodgkin's disease in 1 and aplastic anaemia in 1 patient. Of the patients, 61% were male, and had a median age of 40 years (27-51 years). The median time elapsed from transplantation to ICU admission was 7 weeks (2-28 weeks). Four patients received BMT, whereas the remaining patients received peripheral SCT. Donors were HLA identical, 6/6 matched related donors in 27 patients (61%) and 10/10 matched unrelated donors in 17 patients (39%). The majority of patients received myeloablative conditioning (41 patients), mostly high dose of CY and TBI. Three patients had reduced intensity conditioning, consisting of antithymocyte globuline and CY, together with etoposide and cytarabine (one patient), TBI (one patient) or fludarabine (one patient). Five patients died at the ICU before engraftment; one patient received growth factor support.
The outcome of allogeneic BM transplant patients with acute critical illness is described P Depuydt et al MV was required in 32 patients (73%); two patients with acute respiratory failure did not receive MV because of therapeutic limitation (do-not-resuscitate order). Four patients received non-invasive MV, but all of them were eventually intubated. Acute kidney injury requiring RRT developed in 12 patients (27%); five more patients with acute kidney injury were not treated with RRT because of do-not-resuscitate orders. Overall ICU mortality, in-hospital mortality and 6-month mortality were 61, 75 and 80%, respectively. The time interval between transplantation and ICU admission was significantly shorter in survivors than in non-survivors: 4 weeks (1-53) in ICU survivors vs 10 weeks (2-25) in ICU non-survivors (P ¼ 0.006), 4 weeks (1-52) in hospital survivors vs 12 weeks (2-105) in hospital non-survivors (P ¼ 0.10), and 4 weeks (2-156) in 6-month survivors vs 12 weeks (2-25) in 6-month non-survivors (Po0.001); however, in the timeline following transplantation, we could not identify a clear 'breakpoint' with a stepup in mortality.
Admission diagnosis was bacterial infection in 14 patients (32%), non-bacterial infection in 13 (30%) and non-infectious disease in 17 patients (38%) ( Tables 1 and  2 ). Admission diagnosis is further detailed in Table 1 .
Patients with bacterial infection tended to have a shorter time interval between transplant and ICU admission than the other categories. However, as there was a large overlap between the three categories, we could not identify a time frame when bacterial infection was the predominant cause of ICU admission, as compared with other aetiologies.
Characteristics of the three categories of patients according to principal admission diagnosis are provided in Table 2 . ICU mortality rates in patients with bacterial infection, non-bacterial infection and non-infectious disease were 36, 77 and 71%, respectively (P ¼ 0.05). Hospital mortality rates and 6-month mortality rates for the three categories were 43, 85 and 94% (P ¼ 0.003) and 57, 85 and 94%, respectively (P ¼ 0.03). Of the nine patients surviving beyond 6 months, five are still alive at present (three with bacterial infection, two with nonbacterial infection). In a logistic regression adjusting for sequential organ failure assessment at day 1 and degree of GVHD, bacterial infection (odds ratio 0.06 (0.01-0.36), P ¼ 0.002) was associated with significantly lower odds for in-hospital mortality (Tables 3 and 4) .
In patients requiring MV, RRT or vasopressors, inhospital mortality and 6-month mortality rates were 84, 82 and 61%, and 88, 91 and 72%, respectively. Consistently throughout these subgroups with need for organ support, patients with bacterial infection had lower in-hospital mortality than did patients without (94 vs 71% (MV), 72 vs 100% (RRT) and 46 vs 100% (vasopressors)), although these figures reached no statistical significance; the same held true for 6-month mortality rates (79 vs 94% (MV), 86 vs 100% (RRT) and 62 vs 100% (vasopressors)). In all,10 patients required both MV and RRT; only two of them survived until hospital discharge and one patient was alive at 6 months. Fifteen mechanically ventilated patients also required vasopressors; four of them survived until hospital discharge, and three were alive at 6 months; all of these 6-month survivors with multiple organ failure had bacterial infection as the underlying cause.
Discussion
Mortality rates in the cohort of 44 ABMT/AHSCT patients admitted to our ICU were consistent with recently published figures, both in the full cohort and in the subgroups requiring major support of failing organs (MV, RRT and vasopressor therapy). For comparison, mortality in BMT patients admitted to the ICU was 63% at 6 months in the study by Pene et al., 22 and 67% at 1 year in the study by Scales et al. 4 For patients receiving MV, these same reports yielded mortality rates of 86% (6 months, Pene et al. 22 )) and 87% (1 year, Scales et al. 4 ). However, in addition we were able to observe a dichotomy in mortality relating to the acute illness provoking organ failure, as patients with bacterial infection as principal ICU admission diagnosis had significantly higher odds to survive to hospital discharge, in comparison with patients with non-bacterial infection or non-infectious disease. A similar distinction could be made in the subgroups requiring major support of failing organs. Table 1 Principal admission diagnosis in ABMT/AHSCT patients (n ¼ 44) The outcome of allogeneic BM transplant patients with acute critical illness is described P Depuydt et al Short-term outcome in critically ill patients with solid cancer or haematological malignancy has been shown to be mainly predicted by the number of failing organs, rather than by the underlying neoplasy characteristics. 8, 9, [23] [24] [25] Acute respiratory failure (ARF) with need for MV is the most common reason for ICU referral in these patients and is a very strong predictor for poor outcome. Moreover, whereas prognosis for mechanically ventilated cancer patients (including haematological patients) in general has improved over the last two decades, this trend has not been observed in ABMT/AHSCT patients, in whom ICU and inhospital mortality rates have not reduced below 80%. 10, 19 Whereas this figure also held true for our full cohort of mechanically ventilated AHSCT patients, we discerned that this was due to the extremely poor outcome in patients with a non-bacterial infectious disease or a non-infectious cause Table 2 Characteristics and outcome of ABMT/AHSCT patients a according to principal admission diagnosis
Bacterial infection (n ¼ 14)
Nonbacterial infection (n ¼ 13)
Noninfectious cause (n ¼ 17) The outcome of allogeneic BM transplant patients with acute critical illness is described P Depuydt et al of ARF. On the other hand, survival in patients with bacterial infection causing, or contributing to, ARF had a 33% hospital survival, comparable to that reported recently in non-transplant cancer patients with ARF.
11,26
The association between bacterial infection as the cause of critical illness and a more favourable outcome in ABMT/AHSCT patients has previously been observed in our general population of critically ill haematological patients.
12,27 As we argued before, this observation is probably because of the reversible cause of the factor that provokes critical illness, as bacterial sepsis can be effectively contained by early appropriate antimicrobial therapy and aggressive resuscitation. Consistent with this hypothesis is the reduction in sequential organ failure assessment score observed over the first five days of ICU admission in our patients with bacterial infection, which was absent in the other categories of patients (see Table 2 ).
The observation that ABMT/AHSCT patients with critical illness caused by bacterial infection have acceptable chances for survival beyond the ICU and the hospital, even in the presence of major organ dysfunction, has important implications. As at onset of organ failure it may be difficult to identify the direct cause, patients should at least be offered ICU supportive therapy for immediate stabilization and/or reversal of vital dysfunction, while the underlying cause is aggressively searched for. Second, if bacterial infection is confirmed, or is judged to be highly likely based on the set of clinical characteristics we identified in this and in earlier studies, prolonged ICU support should not be considered as disproportionate care. Although the median ICU length of stay was 5 days in our eight patients with bacterial infection surviving ICU, in three patients this exceeded 14 days, and two of these patients were still alive at 6 months.
In our cohort, some subgroups were identified with particularly poor outcome: patients without bacterial infection requiring RRT or vasopressor therapy, and patients requiring both MV and RRT, regardless of the underlying cause. However, as the size of our cohort is rather small, these results should, in our opinion, not be used to deny critically ill patients without apparent bacterial infection but with good prospects for haematological cure an ICU trial. Moreover, as diagnosis of a noninfectious cause requires exclusion of infection, which is not always reliable because of nonspecific clinical signs and lower yield of cultures because of empirical broad-spectrum therapy, misclassification of patients may be of some concern. Nevertheless, these poor outcome figures should be taken into account when discussing ICU referral with the attending haematologist, when informing the patient and his or her next of kin about the prospects, and when defining set goals for an ICU trial.
Similar to the report by Pene et al., 22 we found that patients surviving beyond critical illness had a shorter time interval between transplantation and ICU admission, but in contrast, we could not link better survival with the initial engraftment period, defined as the time frame of 1 month following transplant. In our patients, there was a significant association between a shorter interval 'transplant-ICU admission' and a bacterial cause of ICU, which may partly explain this finding. Pene et al. did not report on the relationship between outcome and (bacterial) infection or between time of ICU admission and (bacterial) infection. As such, for this study it can only be speculated whether differences in the underlying cause accounted for the better outcome of patients admitted to the ICU within the initial engraftment period.
A limitation of our study, hampering extrapolation, is that admission policy may have influenced outcome, and that different selection of ABMT/AHSCT patients may shift mortality rates in one or the other direction. However, no generally accepted or standardized admission criteria for ICU referral of these patients exist, and close consultation between the attending haematologist and the ICU physician on a patient-to-patient basis may be still the best way to select patients. Moreover, as we outlined before, the outcome parameters for the full cohort are closely comparable to that of recent multicentre studies.
In summary, our data add to the growing body of evidence indicating that ICU referral of ABMT/AHSCT patients is justifiable, as a significant proportion of patients have good longer-term outcome. In addition, prolonged organ support should be considered, especially in patients in whom bacterial infection is thought to have triggered critical illness.
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